Ideaya Biosciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary
05/08/2025 12:35
IDEAYA Biosciences Inc IDYA.OQ reported a quarterly adjusted loss of 88 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -68 cents. The mean expectation of thirteen analysts for the quarter was for a loss of 79 cents per share. Wall Street expected results to range from -90 cents to -54 cents per share. Reported revenue was zero; analysts expected $3.89 million. IDEAYA Biosciences Inc's reported EPS for the quarter was a loss of 88 cents. The company reported a quarterly loss of $77.49 million. IDEAYA Biosciences Inc shares had risen by 18.9% this quarter and lost 2.7% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 3.4% in the last three months. In the last 30 days, there have been no negative revisions of earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for IDEAYA Biosciences Inc is $47.00, about 46.8% above its last closing price of $25.00 This summary was machine generated from LSEG data August 5 at 11:35 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -0.79 | -0.88 | Missed |
| Mar. 31 2025 | -0.66 | -0.82 | Missed |
| Dec. 31 2024 | -0.64 | -1.49 | Missed |
| Sep. 30 2024 | -0.63 | -0.60 | Beat |
Recent news on IDEAYA Biosciences
See all newsBrief: Ideaya Biosciences And Servier Announce Data From Three Clinical Trials At Esmo 2026 Supporting The Potential Of Darovasertib To Become A Foundational New Therapy For Patients Across The Treatment Journey Of Uveal Melanoma
Brief: Ideaya Biosciences Announces The Promotion Of Dr. Michael White To President, Research And Development
Brief: Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ideaya Biosciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj